ABSTRACT: A novel class of benzoheterocyclic analogues of amodiaquine designed to avoid toxic reactive metabolite formation was synthesized and evaluated for antiplasmodial activity against K1 (multidrug resistant) and NF54 (sensitive) strains of the malaria parasite Plasmodium falciparum. Structure-activity relationship studies led to the identification of highly promising analogs, the most potent of which had IC50s in the nanomolar range against both strains. The compounds further demonstrated good in vitro microsomal metabolic stability while those subjected to in vivo pharmacokinetic studies had desirable pharmacokinetic profiles. In vivo antimalarial efficacy in Plasmodium berghei infected mice was evaluated for four compounds, all of which showed good activity following oral administration. In particular, compound 19 completely cured treated mice at a low multiple dose of 4×10 mg/kg. Mechanistic and bioactivation studies suggest hemozoin formation inhibition and a low likelihood of forming quinone-imine reactive metabolites, respectively. KEYWORDS: amodiaquine, benzoxazole, antiplasmodial activity, antimalarial activity, malaria, reactive metabolite, 4-aminoquinolines; bioactivation; structure-activity relationship; β-hematin; quinone imine.
INTRODUCTION
Malaria remains a leading cause of morbidity and mortality globally. In 2012, there were an estimated 207 million cases of malaria and 627 000 deaths worldwide, with 90% of all malaria deaths occurring in sub-Saharan Africa. 1 One of the biggest challenges facing malaria chemotherapy is the rapid emergence of resistance to existing antimalarial drugs. 2 This challenge underscores the need for the continued search for new antimalarials.
Chloroquine (1) (structure shown in Figure 1 ), was undoubtedly one of the most successful antimalarials ever owing to its good efficacy and low cost which made it affordable especially in the developing countries with high malaria endemicity. 3 Chloroquine was replaced as first line therapy by the sulfonamide antimalarials and, later on, artemisinin combination therapy (ACT), following the development of widespread resistance against the drug by Plasmodium falciparum. 4 An aromatic side chain analogue of chloroquine, amodiaquine (2) , however, retains activity against chloroquine-resistant Plasmodium strains. 5 Besides, it is an established fact that resistance against these 4-aminoquinolines is not a result of target modification but is caused by impaired accumulation of the drug at the target. 6, 7 Consequently, amodiaquine is an attractive lead compound in the search for new antimalarials. Despite the desirable antimalarial efficacy of amodiaquine, chronic use especially during prophylaxis has been found to precipitate severe hepatotoxicity, myelotoxicity and agranulocytosis. 8, 9 This toxicity has been attributed to the bioactivation of amodiaquine to reactive quinone imine (3) and aldehyde quinone imine (4) metabolites (figure 1) which covalently bind to cellular macromolecules causing drug-induced toxicity and cell damage directly or via immunological mechanisms. [10] [11] [12] <<figure 1>>
The avoidance of amodiaquine bioactivation has been the subject of a number of previous studies.
Park and co-workers have demonstrated that the 4′-hydroxyl group of amodiaquine could be replaced with a 4′-fluorine atom to produce 4'-dehydroxy-4'-fluoroamodiaquine (5) with antimalarial activity in the low nanomolar range. 11, 13 Miroshnikova and coworkers synthesized various isotebuquine analogs (6) with excellent antimalarial activity but poor oral bioavailability. 14 The most successful campaign towards circumventing amodiaquine bioactivation was the synthesis of isoquine (7) and its analogues by O'Neill and co-workers. 15 One of these analogues, N-tert-butyl isoquine (8) , progressed to clinical trials but its development has been discontinued due to exposures insufficient to demonstrate drug safety superior to chloroquine. [16] [17] [18] Figure 2 shows the chemical structures of some of the compounds synthesized to circumvent amodiaquine bioactivation.
<<figure 2>>
In a previous paper, we reported for the first time the synthesis and potent antiplasmodial activity of benzothiazolyl (9) (10) (11) (12) (13) , benzimidazolyl (14) (15) (16) (17) , benzoxazolyl (18) (19) and pyridyl (20) (21) analogues of amodiaquine (figure 3) designed to prevent bioactivation to both the quinone imine and aldehyde metabolites. 19 The present paper reports on the bioactivation studies on these compounds and the selection, expanded synthesis and structure activity relationship (SAR) studies of the benzoxazole analogues. The in vitro antiplasmodial, mechanistic and metabolic stability evaluation as well as in vivo pharmacokinetic and efficacy studies on this class of compounds is presented.
<<figure 3>>
Bioactivation potential can be evaluated using various approaches including covalent binding studies and trapping with different reagents following incubation with microsomes or hepatocytes. 20 The trapping reagents used include glutathione (for soft electrophiles such as the quinone imine) as well as methoxylamine and potassium cyanide (for hard electrophiles such as the iminium ion). [21] [22] [23] Electrochemical oxidation online with electrospray ionization mass spectrometry (EC-ESI/MS) is a relatively new technique that avoids the complexity of working with biological matrices. Electrochemical oxidation has been found to successfully mimic CYP450 benzylic hydroxylation, hydroxylation of aromatic rings containing electron-donating groups, Ndealkylation, S-oxidation, dehydrogenation and, less efficiently, N-oxidation and Odealkylation.
oxidation to mimic CYP450 and liver microsome catalyzed oxidation of amodiaquine and desethylamodiaquine. 25 Other researchers have employed electrochemistry to mimic phase I oxidation of paracetamol, clozapine, trimethoprim and diclofenac. 26, 27 The coupling of EC with MS means that MS/MS can be used to provide important structural information about the reactive metabolites formed.
RESULTS AND DISCUSSION

Bioactivation studies on previously synthesized analogues
The bioactivation potential of our previously synthesized analogues 9-21 was evaluated using trapping experiments involving glutathione, potassium cyanide and methoxylamine. The EC-ESI/MS system was utilized whereby mass spectra were scanned for the presence of adduct peaks arising from covalent bond formation between any reactive intermediates produced (upon oxidative bioactivation) and the trapping agents.
The results of the glutathione trapping experiment were semi-quantitatively expressed as the ratio of the sum of test compound adduct peak areas to clozapine adduct peak area and were represented graphically (figure 4). Clozapine is commonly used as a model compound that undergoes bioactivation to a nitrenium intermediate which, in turn, readily forms a glutathione conjugate. 28, 29 A value of zero implies that no adduct was detected for the test compound while a value greater than one implies the sum of adduct peak areas for the test compound is greater than the area of the clozapine adduct peak. This implies that the compound has a higher potential for bioactivation than clozapine. Our study demonstrated that benzoxazole analogues 18 and 19 had the lowest potential for bioactivation to the quinone imine metabolite. 30 Benzothiazole analogues 9, 11 and potential for bioactivation to soft electrophilic metabolites. The proposed bioactivation mechanisms, facilitated by the more nucleophilic nitrogen and sulphur atoms, to quinone-like intermediates for the benzothiazolyl, benzimidazolyl and pyridyl series are shown in figure 5 .
<<figure 4>> <<figure 5>>
Results for the trapping of hard electrophiles using potassium cyanide and methoxylamine were expressed as positive or negative depending on the detection or lack thereof, respectively, of cyanide and methoxylamine adduct peaks in the spectra of the test compounds (figure 4). The benzothiazole tert-butyl side chain analogue 9, the benzimidazole ethyl side chain analogue 14 and the benzoxazole ethyl side chain analogue 18 did not undergo trapping with either reagent.
We concluded that trapping was purely dependent on the nature of the side chain, such that only molecules with a highly basic tertiary amine on the side chain could form reactive species capable of reacting with potassium cyanide and methoxylamine. Such an observation can be explained using the well known metabolic pathway for tertiary amines which involves formation of iminium ions and aldehydes. 31 Our previous results (table 1) had shown that a highly basic tertiary amine side chain gave the most potent antiplasmodial activity. Thus a functional group considered essential for activity was also involved in bioactivation. However, the aldehyde metabolite of amodiaquine is conjugated with the aminophenol ring and, therefore, relatively stable. The aldehyde metabolite formed by these compounds is attached to the benzoxazole nucleus via a labile amino group. The low bioactivation potential of the benzoxazole series in the glutathione trapping experiment made this series attractive for further exploration. <<Table 1>>
Chemistry
The synthesis of novel benzoxazoles 22-41 starting with 2-amino-4-nitrophenol, carried out as previously described, is shown in scheme 1. 19 Novel analogues 42 and 43 were synthesized by a one step coupling of appropriately substituted commercially available benzoxazole-5-amines with 4,7-dichloroquinoline. <<scheme 1>>
In vitro antiplasmodial activity
The two previously reported benzoxazole analogues (18 Further exploratory studies involved the synthesis of analogues in which the side chain was attached to the benzoxazole group via a carbon instead of a nitrogen atom ( Table 2 ). Although analogue 42 had a highly basic nitrogen, it showed remarkably reduced activity against both strains (NF54 IC50 = 0.213 μM, K1 IC50 = 0.411 μM) compared to the alkylamino or cycloalkylamino analogues. The reduction in activity could not simply be accounted for by the low predicted pKa (7.75) since the morpholino analogues with even lower pKas showed better activity. Attachment to the benzoxazole ring via a carbon atom was, therefore, considered to adversely affect antiplasmodial activity. Analogue 43 only exhibited micromolar activity (NF54 IC50 = 1.094 μM, K1 IC50 = 2.111 μM), probably due to the presence of a carbon linker and the lack of a highly basic nitrogen.
When the alkylamino groups were replaced with substituted benzylamines (31 and 32), activity dropped to the low submicromolar range. The benzylamine analogues were less active than chloroquine against the NF54 strain and virtually equipotent with the drug against the K1 strain.
The methylpyridine analogues (33, 35 and 36) had activity in the mid-submicromolar to low micromolar range with activity increasing in the order 4-methyl < 2-methyl < 3-methyl. Increasing the length of the linker from a methyl to an ethyl as in 34 did not affect activity when compared to the corresponding 2-methylpyridine analogue 33. As with the rest of the analogues discussed above, these compounds were more active against the chloroquine-sensitive NF54 strain as compared to the multidrug-resistant K1 strain.
Among the piperazinyl linker analogues, the methylpiperazine analogue with the piperazine ring directly attached to the benzoxazole ring 39 was more active than the corresponding 1-amino-4-methylpiperazinyl analogue 37. Whereas all the intermediates tested were considered inactive (IC50>20 μM), intermediate 19d with a highly basic tertiary nitrogen showed low micromolar activity against both plasmodial strains (SI Table 1 ). Overall, these findings pointed to the fact that the quinoline ring was essential for antiplasmodial activity. Compounds with potent antiplasmodial activity exhibited good selectivity for Plasmodium falciparum over Chinese hamster ovary cells as seen from the high selectivity indexes in table 2.
β-Hematin inhibition studies
The two previously reported benzoxazole analogues (18 and 19) and the newly synthesized analogues 22-43 were subjected to the β-hematin inhibition assay using a previously described procedure 32 in an attempt to establish whether or not these compounds exert their antiplasmodial effect similarly to other 4-aminoquinolines. The results of the β-hematin inhibition assay (table 2) were correlated with the antiplasmodial activity against the NF54 strain in which resistance A statistically significant linear correlation was found between the logP of the compound with the inverse of the β-hematin inhibition activity (data supplied in SI Table 2 
In vitro microsomal metabolic stability studies
Microsomal metabolic stability was evaluated using a single-time-point assay in which the percentage of parent compound remaining after 30 minutes incubation of the test compound in the presence of pooled human liver or mouse liver microsomes (HLMs or MLMs) and NADPH was determined. 34 The two previously reported benzoxazole analogues (18 In MLM incubations, the analogues were at least twice as stable as amodiaquine except for 23 with only 41 % of the parent compound remaining after 30 minutes. It was apparent that in MLMs the metabolic stability of the cycloalkylamino compounds decreased in the order morpholine analogues > pyrrolidine analogues > piperidine analogues. <<figure 7>>
In vivo pharmacokinetic studies
The pharmacokinetic evaluation of compound 24 was performed in C57Bl/6 mice following oral and intravenous administration, n = 3 over 24 hours. Linear and semi-log plots are shown in figure   8 . Non-compartmental analysis was performed and the results given in 
CONCLUSION
A novel series of orally active antimalarial benzoxazole-4-aminoquinolines has been identified. with water (2×10 ml), a solution of saturated NaHCO3 (only employed when bromo-substituted reactants were used to neutralize HBr), brine (10 ml) and dried over MgSO4. The solvent was removed under vacuum to obtain the products in crude mixture. Column chromatography using a MeOH: EtOAc (0-20%) (for tertiary amine products) or a hexane: EtOAc gradient afforded the pure products. The aromatic nitro-compound (1 mmol) was dissolved in ethanol (8 ml) with warming in a hydrogenator bottle. 10% Pd/C (0.3 times the weight of the compound being reduced) was added to this solution. The reaction bottle was sealed, filled with H2 and evacuated twice. It was then shaken on a Parr shaker for 12 h at 60 psi of H2 until completion of the reaction (monitored by TLC). The reaction mixture was filtered through Celite and the solvent removed under vacuum to obtain the aromatic amine. The aromatic amine (1 mmol, 1 eq) was mixed with 4,7-dichloroquinoline (1.1 eq) in acetonitrile (25 ml). The mixture was acidified with 3-5 drops of
HCl and stirred at reflux for 24 h. The solvent was removed under vacuum after which the residue was dissolved in EtOAc (or 20% methanol in dichloromethane for tertiary amine compounds) and washed with saturated NaHCO3 (3×20 ml) and brine (1×10ml). The combined organic fractions were dried over anhydrous MgSO4, adsorbed onto silica gel (5g) and subjected to silica gel column chromatography to afford the target compounds. 
N 5 -(7-Chloroquinolin-4-yl)-N 2 -(2-(pyrrolidin-1-yl)ethyl)-benzoxazole-2,5-diamine
1-(3-(5-(7-Chloroquinolin-4-ylamino)benzoxazol-2-ylamino)propyl)pyrrolidin-2-one,
N 5 -(7-Chloroquinolin-4-yl)-N 2 -(3-(piperidin-1-yl)propyl)benzoxazole-2,5-diamine, 24
58 % yield. mp 87-89 °C. 1 
In vitro P. falciparum assay and in vivo antimalarial efficacy studies.
Compounds were screened against multidrug resistant (K1) and sensitive (NF54) strains of P.
falciparum in vitro using the modified [ 3 H]-hypoxanthine incorporation assay. 36 In vivo efficacy was conducted as previously described, 37 with the modification that mice (n = 3) were infected with a GFP-transfected P. berghei ANKA strain (donated by A. P. Waters and C. J. Janse, Leiden
University, The Netherlands), and parasitemia was determined using standard flow cytometry techniques. The detection limit was 1 parasite in 1,000 erythrocytes (that is, 0.1%). Activity was 
β-Hematin formation inhibition assay
The β-hematin formation inhibition assay method described by Carter et al. was modified for manual liquid delivery 38, 39 . Two stock solutions of the samples were prepared by dissolving the pre-weighed compound in DMSO with sonication to give 20 mM and 2 mM solutions of each sample. These were delivered to a 96-well plate in duplicate to give concentrations ranging from Sunnyvale, CA, USA). Sigmoidal dose-response curves were fitted to the absorbance data using GraphPad Prism v3.02 to obtain a 50 % inhibitory concentration (IC50) for each compound.
Cytotoxicity assay against CHO cells
Test samples were screened for in vitro cytotoxicity against a mammalian cell-line, Chinese
Hamster Ovarian (CHO) using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT)-assay. The MTT-assay is used as a colorimetric assay for cellular growth and survival, and compares well with other available assays. 41, 42 The tetrazolium salt MTT was used to measure all growth and chemosensitivity. Test samples were tested in triplicate on one occasion. The test samples were prepared to a 20 mg/ml stock solution in 100 % DMSO. Stock solutions were stored at -20ºC. Further dilutions were prepared in complete medium on the day of the experiment.
Samples were tested as a suspension if not completely dissolved. Emetine was used as the reference drug in all experiments. The initial concentration of emetine was 100 μg/ml, which was serially diluted in complete medium with 10-fold dilutions to give 6 concentrations, the lowest being 0.001 μg/ml. The same dilution technique was applied to the all test samples. The highest concentration of solvent to which the cells were exposed to had no measurable effect on the cell viability (data not shown). The 50% inhibitory concentration (IC50) values were obtained from full dose-response curves, using a non-linear dose-response curve fitting analysis via GraphPad Prism v.4 software.
Microsomal stability assay
This assay was conducted in 96-well plate format according to a previously reported method. 34 Test compounds and controls were prepared from 10 mM DMSO stock solutions. 0. 
Pharmacokinetic evaluation in mice
In vivo pharmacokinetics was analysed in six, 8-week-old male C57BL/6 mice divided into an intravenous and oral dosage group, n = 3. (2000 ng/ml) and high (4000 ng/ml) quality controls. Non-compartmental analysis was performed on 24 using Summit PK solutions™ (Summit Research Services, Montrose, USA).
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